Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.

Reimar W. Thomsen,Jakob S. Knudsen,Johnny Kahlert,Lisbeth M. Baggesen,Maria Lajer,Pia H. Holmgaard,Ola Vedin,Anastasia Ustyugova,Henrik Toft Sørensen

Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.

2021

Reimar W. Thomsen
Jakob S. Knudsen
Johnny Kahlert
Lisbeth M. Baggesen
Maria Lajer
Pia H. Holmgaard
Ola Vedin
Anastasia Ustyugova
Henrik Toft Sørensen

Background In cardiovascular outcome trials, the sodium glucose cotransporter 2 inhibitor empagliflozin and glucagon‐like peptide‐1 (GLP‐1) receptor agonist liraglutide caused similar reductions in...

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations